ERBB2 and breast cancer: Moreover, clinical results obtained with sunitinib in phase III studies and with imatinib (also a KIT inhibitor) in phase II studies utilizing broad populations of patients with HER2-negative advanced breast cancer (without selection for any biomarker), whether alone or in combination with cytotoxic chemotherapies, have been disappointing [20-26].